Navigation Links
Green algae move to the beat
Date:10/25/2013

This news release is available in German.

The beating of flagella is one of the basic principles of movement in the cellular cosmos. However, up to now, scientists were unsure as to how the movements of several of these small cellular appendages are synchronised. Dresden-based researchers from the Max Planck Institute of Molecular Cell Biology and Genetics and the MPI for the Physics of Complex Systems have now succeeded in demonstrating how the green alga Chlamydomonas synchronises the movements of its two flagella using a resourceful rocking movement. To do this, the researchers started by developing a theoretical model which they were then able to substantiate in experiments with the microscopic breaststroke swimmers: when the two flagella lose their rhythm, the cell begins to rock. This causes the swimming movements to slow down or accelerate. The resulting synchronisation mechanism is based solely on the coupling of the two movements of the body and the flagella; no special sensors or chemical signals are needed.

"An alga is a wonderful model for investigating our research question because, with its two flagella, it shows us very clearly how several of these appendage-like structures are synchronised using mechanical forces alone," says Benjamin Friedrich from the Max Planck Institute for the Physics of Complex Systems who headed the studies. How tens of thousands of molecular engines work together to set flagella in motion and synchronise them is a matter of great interest, as this mechanism underlies numerous processes: "The tiny cellular appendages are one of nature's greatest hits: they drive sperm and form big conveyor belts in the fallopian tubes and airways," explains Friedrich.

The cellular extensions, which are a mere ten micrometres long, b
'/>"/>

Contact: Dr. Veikko Geyer
geyer@mpi-cbg.de
49-351-210-2891
Max-Planck-Gesellschaft
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Team uses forest waste to develop cheaper, greener supercapacitors
2. Walgreens Mike Ellis Named First President of National Association of Specialty Pharmacy (NASP)
3. Turfgrass tested in shallow green roof substrates
4. QUT develops software to reduce greenhouse gases
5. Green photon beams more agile than optical tweezers
6. A greener, more sustainable source of ingredients for widely used plastics
7. Sediment trapped behind dams makes them hot spots for greenhouse gas emissions
8. Deserts greening from rising CO2
9. Greenhouse gas likely altering ocean foodchain
10. Making hydrogenation greener
11. 21 percent of homes account for 50 percent of greenhouse gas emissions
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Green algae move to the beat
(Date:7/31/2015)... China , 31 de julio de 2015 ... www.icg-10.org ) se celebrará por medio de BGI del 22 al ... . Este año, la conferencia celebra ... ICG se ha convertido en una de las reuniones anuales ... ser una de las reuniones más dinámicas, entusiastas y mejores ...
(Date:7/31/2015)... , Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market and ... has filed provisional patent 62/198989 for ELECTRONIC ... highlights a method to advance crypto-currencies such as Bitcoin ... a common, uniform way to manage all payments.  ...
(Date:7/30/2015)... 30, 2015 Cellecta, Inc., a U.S.-based ... analysis and biomarker discovery, announced the release of ... targeting all human protein coding genes. CRISPR technology ... a gene,s function. Cellecta,s new Human Whole Genome ... tool so that researchers can investigate in a ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2
... of 45 genes coding for antibacterial drug resistance ... of hospital-acquired infections worldwide. The study was ... "We expected to find resistance genes," said lead ... Genomic Information Laboratory at France's National Center for ...
... The octopus arm is extremely flexible. Thanks to ... virtually infinite number of "degrees of freedom"--the octopus ... movements that is unmatched by the human arm. ... differences between the octopus and vertebrates, the octopus ...
... in 1 in every 1,000 births and cause 1 in 20 ... failure of cells within the neural tube to migrate to the ... study in this week's issue of Nature is the first to ... the correct local within the developing neural tube of vertebrates. ...
Cached Biology News:Supersized 'island' of resistance genes discovered in an infectious bacterium 2How the octopus forms an elbow 2
(Date:8/28/2015)... Aug. 28, 2015 /PRNewswire/ - RepliCel Life Sciences ... medicine company focused on the development of autologous ... quarter ended June 30, 2015, corporate highlights, and ... report are available at www.sedar.com ,  ... "RepliCel expects to launch its RCS-01 ...
(Date:8/27/2015)... ... 27, 2015 , ... The Kansas City Animal Health Investment ... health companies to hear from animal health companies with the newest technology. Companies ... agreements or distribution contracts. This meeting is one of the only investment ...
(Date:8/27/2015)... , Aug. 27, 2015 /PRNewswire/ - Portage ... Exchange: PBT.U), and Biohaven Pharmaceutical Holding Company Limited ... a Phase I study of BHV-0223, a glutamate ... (IND) regarding BHV-0223 and recently obtained clearance from ... proceed with human testing. Portage holds 54% equity ...
(Date:8/27/2015)... - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced ... 2015. Biorem,s complete second quarter financial statements and MD&A have been ... except earnings per shareThree-months ended , Six -months endedJune 30 , ... , 2014 Revenue , 4,709 , ... , 1,656 , 56 , 3,188 ...
Breaking Biology Technology:RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3
... on its flagship,suite of medication and infusion management ... and an industry-first Performance,Analytics Service that provides hospitals ... , The ... features that can help hospitals increase the security ...
... Rigel,Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced that ... in a panel,discussion at the 2008 RBC Capital Marketing Healthcare ... Rheumatology", will take,place on Wednesday, December 10, 2008 at 10:00 ... City. , To access ...
... - Albuferon (albinterferon alfa-2b) met its primary endpoint of non-inferiority ... patients with genotypes 2 and 3 chronic hepatitis C - ... receiving 900-mcg Albuferon had comparable rates of serious adverse events, ... peginterferon alfa-2a - , , ...
Cached Biology Technology:Cardinal Health Launches Pyxis(R) MedStation(R) 4000; Introduces Industry-First Service to Interpret Dispensing and Infusion Data 2Cardinal Health Launches Pyxis(R) MedStation(R) 4000; Introduces Industry-First Service to Interpret Dispensing and Infusion Data 3Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 2Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 3Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 4Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 5Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 6Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 7Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 8Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 9
... an automated, confocal, real-time, single cell kinetic ... integrated into a single, compact unit. ... high-resolution, automated confocal imaging with sophisticated imaging ... assays. The system allows the user to ...
... E-PAGE Gels easier and more efficient by ... several types of pre-cut pre-assembled membrane/filter paper ... 13.5 cm E-PAGE Gels*. The available nitrocellulose ... western transfer of proteins (Figure 1 Table ...
... intended for laboratory research use only. ... buffered formalin and embedded in paraffin. ... certified pathologists. Tissue cores were removed ... a new recipient paraffin block, in an ...
... CAST Equine EIA Principle: ... LTC4, LTD4 and LTE4 are ... by 5-lipoxygenase and glutathione-S-transferase. In ... termed "Slow Reacting Substances of ...
Biology Products: